


## Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma

### Graphical abstract



### Authors

Kevin Bi, Meng Xiao He, Ziad Bakouny, ..., Aviv Regev, Toni K. Choueiri, Eliezer M. Van Allen

### Correspondence

eliezerm\_vanallen@dfci.harvard.edu

### In brief

Bi et al. dissect the cancer cell and immune microenvironmental transcriptional programs in immune checkpoint blockade-exposed metastatic renal cell carcinoma, revealing immune subpopulation reprogramming and interactions with distinct cancer cell populations in the context of clinical resistance.

### Highlights

- Distinct CD8<sup>+</sup> T cell phenotypes are enriched after immune checkpoint blockade (ICB)
- Immune checkpoint ligands are upregulated in macrophages and tumor cells after ICB
- Two cancer cell subpopulations are conserved across heterogeneous RCC tumors
- Cancer cell programs drive distinct immune interactions and predict patient outcomes



## Article

# Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma

Kevin Bi,<sup>1,2,3,11</sup> Meng Xiao He,<sup>1,3,4,11</sup> Ziad Bakouny,<sup>1</sup> Abhay Kanodia,<sup>1,2,3</sup> Sara Napolitano,<sup>1,2,3</sup> Jingyi Wu,<sup>1,2,3</sup> Grace Grimaldi,<sup>1,2,3</sup> David A. Braun,<sup>1,3,5</sup> Michael S. Cuoco,<sup>3</sup> Angie Mayorga,<sup>1,2</sup> Laura DelloStritto,<sup>1,2</sup> Gabrielle Bouchard,<sup>1</sup> John Steinharter,<sup>1</sup> Alok K. Tewari,<sup>1,5</sup> Natalie I. Vokes,<sup>1,3</sup> Erin Shannon,<sup>3</sup> Maxine Sun,<sup>1</sup> Jihye Park,<sup>1,3</sup> Steven L. Chang,<sup>6</sup> Bradley A. McGregor,<sup>1</sup> Rizwan Haq,<sup>1,3</sup> Thomas Denize,<sup>5,7</sup> Sabina Signoretti,<sup>5,7,8</sup> Jennifer L. Guerriero,<sup>5,9</sup> Sébastien Vigneau,<sup>1,2,3</sup> Orit Rozenblatt-Rosen,<sup>3</sup> Asaf Rotem,<sup>1,2,3</sup> Aviv Regev,<sup>3,10</sup> Toni K. Choueiri,<sup>1,5,12</sup> and Eliezer M. Van Allen<sup>1,2,3,12,13,\*</sup>

<sup>1</sup>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA

<sup>2</sup>Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA 02115, USA

<sup>3</sup>Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA

<sup>4</sup>Harvard Graduate Program in Biophysics, Boston, MA 02115, USA

<sup>5</sup>Harvard Medical School, Boston, MA 02115, USA

<sup>6</sup>Division of Urology, Brigham and Women's Hospital, Boston, MA 02115, USA

<sup>7</sup>Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA

<sup>8</sup>Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02115, USA

<sup>9</sup>Breast Tumor Immunology Laboratory, Women's Cancer Program, Dana-Farber Cancer Institute, Boston, MA 02215, USA

<sup>10</sup>Howard Hughes Medical Institute and Koch Institute for Integrative Cancer Research, Department of Biology, MIT, Cambridge, MA 02139, USA

<sup>11</sup>These authors contributed equally

<sup>12</sup>Co-senior authors

<sup>13</sup>Lead contact

\*Correspondence: [eliezerm\\_vanallen@dfci.harvard.edu](mailto:eliezerm_vanallen@dfci.harvard.edu)

<https://doi.org/10.1016/j.ccell.2021.02.015>

## SUMMARY

Immune checkpoint blockade (ICB) results in durable disease control in a subset of patients with advanced renal cell carcinoma (RCC), but mechanisms driving resistance are poorly understood. We characterize the single-cell transcriptomes of cancer and immune cells from metastatic RCC patients before or after ICB exposure. In responders, subsets of cytotoxic T cells express higher levels of co-inhibitory receptors and effector molecules. Macrophages from treated biopsies shift toward pro-inflammatory states in response to an interferon-rich microenvironment but also upregulate immunosuppressive markers. In cancer cells, we identify bifurcation into two subpopulations differing in angiogenic signaling and upregulation of immunosuppressive programs after ICB. Expression signatures for cancer cell subpopulations and immune evasion are associated with *PBRM1* mutation and survival in primary and ICB-treated advanced RCC. Our findings demonstrate that ICB remodels the RCC microenvironment and modifies the interplay between cancer and immune cell populations critical for understanding response and resistance to ICB.


## INTRODUCTION

The tumor microenvironment plays critical roles in renal cell carcinoma (RCC) carcinogenesis, pathophysiology, and therapy. The most common RCC histologic subtype, clear cell RCC (ccRCC), frequently harbors characteristic second-hit loss-of-function mutations in *VHL* on a background of loss of chromosome 3p, where *VHL* resides (Creighton et al., 2013). These events result in decreased degradation of hypoxia-inducible factors (HIFs), causing mutant cells to shift to using glycolysis and secreting VEGF, which promotes angiogenesis (Hsieh et al., 2017). Moreover, ccRCC tumors are highly infiltrated by immune

cells, particularly by T cells (Şenbabaoğlu et al., 2016). Leveraging these features of the microenvironment, treatment has evolved significantly over the past decade, with now widespread use of VEGF tyrosine kinase inhibitors (TKIs), immune checkpoint blockade (ICB), and combinations of these approaches (Choueiri and Motzer, 2017; Motzer et al., 2014, 2019; Rini et al., 2019).

ICB can provide durable benefit in responders, but resistance occurs in most patients, and the causal cancer and immune cellular processes are poorly understood. Genomic characterization of ICB response has focused on bulk-sequenced pre-treatment samples, where lower baseline myeloid inflammation





**Figure 1. Characterizing the tumor microenvironment of advanced RCC during therapy**

(A) Study overview.

(B) Summary of treatment histories at time of biopsy, clinicopathological features, and genomic features across profiled RCC lesions. ICB Response: PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable. For some samples without successful whole-exome sequencing, genomic characterization is incomplete or missing.

(C) Uniform manifold approximation and projection (UMAP) of malignant and non-malignant cells captured across all lesions, colored by broad cell type. Granular cell types and states were discerned through iterative reprojection and unsupervised clustering of lymphoid, myeloid, and tumor compartments, and merged into

(legend continued on next page)

and *PBRM1* loss of function are associated with response in certain patient populations (Braun et al., 2019, 2020; McDermott et al., 2018; Miao et al., 2018). Observations of both intra- and intertumoral heterogeneity complicate mechanistic understanding, with multiple molecular subtypes of ccRCC defined by mutations in a set of chromatin remodelers that exhibit distinct patterns of evolution and metastasis (Creighton et al., 2013; Gerlinger et al., 2012; Turajlic et al., 2018).

Bulk sequencing is poorly suited to investigating cell-type-specific patterns of response to therapy. A lack of representative pre-clinical immune-competent RCC models poses further challenges to investigating interactions and signaling between cell types (Hsieh et al., 2017). To address these challenges, recent studies utilize single-cell analyses of patient samples to pinpoint cancer cell of origin and describe immune cells in untreated RCC (Chevrier et al., 2017; Young et al., 2018). We therefore hypothesized that single-cell transcriptomic dissection of biopsies from before or after ICB exposure would reveal immune and cancer cell programs that determine treatment response and nominate targets to combat resistance.

## RESULTS

### Characterizing the tumor microenvironment of advanced RCC during therapy

We collected fresh biopsies or surgical resections from eight patients, seven with metastatic RCC and one with localized disease (Table S1). Dissociated cells were processed for single-cell RNA sequencing (scRNA-seq) using the 10x platform, and additional tissue was used for bulk whole-exome sequencing where available (Figure 1A). At time of biopsy, five patients had been exposed to ICB (including four to both TKIs and ICB), and three patients had not been exposed to systemic therapy (Figure 1B). Specimens were derived from the kidney in cases of nephrectomy and from lymph node and visceral metastases otherwise. Seven patients had ccRCC, while one tumor had a type 2 papillary RCC histology with *PBRM1* and *SETD2* mutations. As expected, chromosome 3p loss was universally detected in ccRCC patients for whom genomic characterization was available, with additional second-hit mutations in *VHL* and/or genes encoding chromatin remodelers. Broadly, our cohort recapitulated typical characteristics of advanced ccRCC in both genomic and clinical features (Creighton et al., 2013).

After quality control, our dataset included 34,326 total cells covering various cancer and non-malignant cell types. To mitigate possible batch effects and allow for joint analysis of cancer cells, which have patient-specific expression patterns, we used Seurat's CCA-based alignment to aggregate cells across samples and jointly cluster them in an unsupervised manner (Figures 1C and S1A; Table S1) (Butler et al., 2018). We labeled clusters based on marker gene expression, identifying cancer and non-cancer cell clusters shared across patients, biopsy site, and systemic treatment received (Figures 1C, 1D, S1B, and S1C; Table S1).

### CD8<sup>+</sup> T cell remodeling by ICB

All ICB-exposed patients in our cohort received a therapy targeting the PD-1 axis, so we hypothesized that treatment may enact cell-(sub)type-specific remodeling of the lymphoid compartment. To address this, we began by performing unsupervised clustering within broad lymphoid cell types to identify cell states conserved across patients, biopsy sites, and treatment histories. We identified 12 lymphoid cell subsets, including B cells, plasma cells, natural killer T cells, *FGFBP2*<sup>+</sup> and *FGFBP2*<sup>-</sup> natural killer cells, regulatory T cells, and memory and effector T helper cells (Figures 2A, 2B, S2A, and S2B; Table S2).


CD8<sup>+</sup> T cells formed four distinct clusters, including a population progressing through the cell cycle, a small population marked by expression of the interferon-stimulated gene *MX1*, and two populations differentiated by their expression of a set of genes including *TNFRSF9* (encoding the activation marker 4-1BB) (Figures 2A–2C and S2C; Table S2) (Horisberger et al., 1983; Wolff et al., 2007). Co-inhibitory receptors *PDCD1* (encoding PD-1), *HAVCR2* (encoding TIM-3), and *LAG3* were expressed across all CD8<sup>+</sup> T cell subsets but were detected in a larger proportion of 4-1BB-Hi cells (Figure S2C) (Thommen and Schumacher, 2018). *TOX* and *ENTPD1* (encoding CD39), two exhaustion markers upregulated in tumor-specific T cells, were also elevated in 4-1BB-Hi and cycling cells (Figures 2C and S2C) (Canale et al., 2018; Duhon et al., 2018; Scott et al., 2019). In a pattern opposite that of *ENTPD1*, we observed expression, in a subset of cells, of *IL7R* and *STAT4*, two genes linked with T cell longevity and memory that are upregulated in a population of cells associated with ICB response in melanoma (Figure 2C) (Sade-Feldman et al., 2018).

Studies in melanoma models have shown that tumor-infiltrating CD8<sup>+</sup> T cells include a progenitor exhausted population, which persists long term, responds to anti-PD-1 therapy, and ultimately differentiates into terminally exhausted cells. Frequency of this CD8<sup>+</sup> T cell population in pre-treatment biopsies predicts positive clinical outcomes in melanoma treated with ICB (Miller et al., 2019). To determine whether any of the CD8<sup>+</sup> T cell subsets we recovered in RCC resemble this progenitor exhausted phenotype, we scored individual cells for progenitor and terminally exhausted gene signatures (Table S2) (DeTomaso et al., 2019; Sade-Feldman et al., 2018). We found that the progenitor exhausted signature was strongly enriched in a subset of the cells within the 4-1BB-Lo cluster (Figures 2D, 2E, and S3A–S3C). Conversely, the terminally exhausted signature was elevated in the other CD8<sup>+</sup> T cell populations.

Having identified a candidate subset of CD8<sup>+</sup> T cells within RCC that bears some similarities to the previously described progenitor exhausted population, we next examined expression differences based on exposure to ICB (Figure 2F). Among CD8<sup>+</sup> T cell subsets, we found that *PDCD1*, *TIGIT*, and *HAVCR2* were significantly upregulated in ICB-exposed biopsies only within the 4-1BB-Lo cluster, an effect driven by responders (Figure S3D). Of effector molecules, we observed elevated expression in ICB-exposed biopsies of *GZMB*, *PRF1*, and *IFNG* in both

broader cell-type categories for this visualization. DC, dendritic cell; NK, natural killer cell; NKT, natural killer T cell; TAM, tumor-associated macrophage; T-Reg, regulatory T cell.

(D) UMAP of malignant and non-malignant cells captured across all lesions, colored by patient, biopsy site, ICB treatment history, and ICB response. See also Figure S1, Table S1.



**Figure 2. CD8<sup>+</sup> T cell exhaustion states are differentially remodeled by ICB**

(A) UMAP of lymphoid cells captured across all lesions, colored and labeled by cell type. Bar plots show cell-type proportions grouped by ICB treatment history.

(B) Heatmap of scaled normalized expression for cell-type-defining genes as determined by two-sided Wilcoxon rank-sum test with Bonferroni FDR correction ( $q < 0.01$ ).

(C) UMAP of CD8<sup>+</sup> T cell subtypes, followed by expression heatmaps in UMAP space of co-inhibitory receptors, exhaustion markers, and memory-associated genes.

(D) Heatmaps in UMAP space of VISION signature scores for terminally exhausted and progenitor exhausted CD8<sup>+</sup> T cells.

(E) Signature score distributions for terminally exhausted and progenitor exhausted CD8<sup>+</sup> T cell signatures within each CD8<sup>+</sup> T cell subtype. Significance of differential signature enrichment ( $p$  value) between subtypes was determined by two-sided Wilcoxon rank-sum test. Boxplots include centerline, median; box limits, upper and lower quartiles; and whiskers extending at most 1.5 $\times$  the interquartile range past upper and lower quartiles.

(F) Heatmap of differential gene expression  $q$  values (two-sided Wilcoxon rank-sum test with Bonferroni FDR correction) for comparisons of cells within each CD8<sup>+</sup> T cell cluster from ICB-exposed versus ICB-naive patients.

(G) Gene set enrichment analysis (GSEA) of terminally exhausted and progenitor exhausted signatures in 4-1BB-Lo CD8<sup>+</sup> T cells from ICB PR patients compared with ICB SD/PD patients.

(H) Signature scores for an ICB-exposed 4-1BB-Lo CD8<sup>+</sup> T cell signature and expression values for individual genes in paired pre-/on-ICB bulk RNA-seq samples in the Checkmate 009 RCC cohort. Expression values for individual genes were normalized against total CD8 fraction per sample as inferred by CIBERSORTx. Significance of differential signature enrichment or expression ( $p$  value) was determined by paired two-sided Wilcoxon rank-sum test. Boxplots include centerline, median; box limits, upper and lower quartiles; and whiskers extending at most 1.5 $\times$  the interquartile range past upper and lower quartiles.

\*\*\* $p < 0.001$ , two-sided Wilcoxon rank-sum test. See also [Figures S2](#) and [S3](#), [Table S2](#).

4-1BB-Lo and 4-1BB-Hi populations, but only 4-1BB-Lo cells upregulated *GZMA* and *FASLG*. Likewise, only 4-1BB-Lo cells upregulated a host of co-stimulatory molecules and chemokines. Conversely, 4-1BB-Lo cells from ICB-exposed biopsies downregulated several genes associated with the progenitor ex-

hausted phenotype, hinting at possible differentiation toward a more terminally exhausted state. In melanoma models, polyfunctional progenitor exhausted CD8<sup>+</sup> T cells differentiate to a more terminally exhausted phenotype during response to anti-PD1, and the latter population is primarily responsible for tumor

killing despite being short lived (Miller et al., 2019). Within 4-1BB-Lo cells from ICB-exposed patients in our cohort, we observed significant enrichment of the terminally exhausted gene signature in cells from responders compared with cells from non-responders (Figures 2G and S3E–S3G; Table S2).

To validate these phenomena seen in unpaired biopsies, we examined a larger cohort of patients (Checkmate 009) undergoing monotherapy with the anti-PD-1 antibody nivolumab for whom longitudinal pre- and on-therapy bulk transcriptomes were available (Choueiri et al., 2016; Miao et al., 2018). In these paired biopsies, we observed significantly increased levels in the on-therapy samples of an expression signature derived from comparing ICB-exposed with ICB-naive 4-1BB-Lo cells from our single-cell cohort (Figure 2H; Table S2). Concordantly, on-treatment samples exhibited higher levels of co-inhibitory (e.g., *PDCD1*, *LAG3*) and effector molecules (e.g., *IFNG*, *PRF1*). These findings are consistent with, but do not unequivocally establish, the possible existence in RCC of a subpopulation of 4-1BB-Lo CD8<sup>+</sup> T cells that respond to anti-PD1 therapy in a mechanistic fashion similar to that observed in models based on melanoma and chronic viral infection. Longitudinal single-cell studies would be necessary to definitively detect subpopulation-specific treatment-associated differentiation within individual patients.

### Shift toward inflammation in tumor-associated macrophages

In addition to adaptive immunity, the innate immune system plays critical roles in tumor survival and resistance to therapy. In particular, tumor-associated macrophages (TAMs) are reported to play diverse and opposing roles within the tumor microenvironment, with different phenotypes promoting inflammation, tumor growth, angiogenesis, and metastasis, as well as cancer cell killing (Guerriero, 2018; Mantovani et al., 2017). TAMs are diverse in ccRCC, with mass cytometry identifying 17 phenotypes and high myeloid inflammation at baseline associated with worse outcomes on anti-PD-1 therapy (Chevrier et al., 2017; McDermott et al., 2018). Consequently, we sought to characterize myeloid cells within our cohort and their response to therapy.


We extracted myeloid cells identified from the full dataset based on marker expression and sub-clustered them, identifying two clusters of dendritic cells (CLEC9A<sup>+</sup> and CD1c<sup>+</sup> classical dendritic cells), two clusters of monocytes (classical CD16<sup>−</sup> and CD16<sup>+</sup> monocytes), and five clusters of TAMs, which expressed a diverse host of immunomodulatory genes (Figures 3A–3C; Table S3) (Collin and Bigley, 2018). The proportions of these cell populations were stable between patients and across ICB exposure status (Figures 3A and S4A). A simple M1/M2 dichotomization of macrophages into phenotypes that promote inflammation and wound healing/tissue repair, respectively, is increasingly understood to imperfectly capture the diversity of TAM phenotypes, and indeed, we did not observe a clean binarization of expression of M1 and M2 marker genes (Figure 3D; Table S3) (Mantovani et al., 2017). A small population of CXCL10-Hi TAMs specifically expressed a set of genes associated with a classical M1-activated phenotype (Wang et al., 2014). However, the other three noncycling TAM populations expressed different M2-associated genes to varying degrees. Multiple M2-associ-

ated genes were robustly detected in a population of TAMs highly expressing *GPNMB*, previously reported to promote M2 polarization in a mouse model of acute kidney injury (Zhou et al., 2017). A separate population of TAMs with elevated expression of *FOLR2*, canonically described as marking M2 macrophages, expressed a distinct subset of M2-associated genes (Puig-Kröger et al., 2009). A last population of TAMs with mixed expression of both M1- and M2-associated genes was marked by high expression of *VSIR*, which encodes VISTA, a PD-1 homolog that serves as a negative checkpoint that inhibits T cell activation (Lines et al., 2014).

To better understand the roles these diverse TAM populations play in the course of ICB, we examined their expression of immune checkpoint genes and immune-related transcriptional programs. PD-L2 and, to a lesser extent, PD-L1, both ligands for PD-1 signaling mediating immune checkpoint in T cells, were detected sparsely across the TAM populations (Figure 3C). *LGALS9*, *VSIG4*, and *VSIR*, whose protein products promote the T cell immune checkpoint via other pathways, and *SIGLEC10*, which can inhibit inflammatory responses by macrophages, were more broadly detected (Barkal et al., 2019; Das et al., 2017; Lines et al., 2014; Vogt et al., 2006). Comparing ICB-exposed patients with and without response, we noted broad and significant changes in expression patterns indicating a shift toward an M1-like phenotype in response to interferon signaling in all TAM and monocyte populations, except in the CXCL10-Hi TAMs, which already showed evidence of M1 polarization (Figures 3E and S4B). In parallel, we observed systematic increases in expression signatures associated with aspects of macrophage activity, including antigen presentation and proteasome function (Figures 3E and S4C). Collectively, these patterns pointed to a widespread shift to a pro-inflammatory phenotype across TAMs in ICB responders, potentially induced by interferon- $\gamma$  produced by CD8<sup>+</sup> T cells (Figures S4D and S4E). At the same time, we also observed systematic and dramatic upregulation of CD8<sup>+</sup> T cell immune checkpoint and macrophage anti-inflammatory signaling genes in ICB-exposed versus naive TAMs (Figure 3F). Much of this effect was driven by TAMs from patients with ICB response, which had further increases in expression levels of *VSIR*, *VSIG4*, *PD-L2*, and *SIGLEC10* compared with cells from non-responders (all assessed post-ICB) (Figure 3G). Thus, even as TAMs in responders exhibited a more pro-inflammatory phenotype, they also exhibited expression changes that may suppress an inflammatory immune microenvironment, thereby potentially promoting eventual resistance to ICB.

### Two distinct cancer cell subpopulations

To better understand cellular programs active in cancer cells that may drive interactions with the immune system, we next sought to identify shared patterns of expression across cancer cells. We sub-clustered cells identified as malignant via gene expression and copy number alterations (Figure S1B). We aligned sets of cancer cells derived from different biopsies to focus on shared variation in cellular programs across the cohort. Across biopsies, cells formed two major clusters, denoted tumor program 1 (TP1) and tumor program 2 (TP2), with a small number of cells distinguished by cell-cycle progression (Figures 4A and 4B; Table S4). Both TP1 and TP2 cells were recovered from all samples



**Figure 3. Tumor-associated macrophages shift toward inflammation during checkpoint blockade**

(A) UMAP of myeloid cells captured across all lesions, colored and labeled by cell type. Bar plots show cell-type proportions grouped by ICB treatment history. (B) Heatmap of scaled normalized expression for cell-type-defining genes as determined by two-sided Wilcoxon rank-sum test with Bonferroni FDR correction ( $q < 0.01$ ).

(C) Dotplot showing percentage of cells in each cell type expressing immune checkpoint and evasion genes.

(D) Heatmap of scaled normalized expression for curated M1- and M2-associated genes within TAM subtypes.

(E) Heatmap of normalized enrichment scores (NES) for gene sets significantly enriched ( $p < 0.05$ ,  $q < 0.25$ ) in TAM subtypes from ICB PR patients compared with ICB SD/PD patients.

(F) Violin and boxplots comparing expression distributions of immune checkpoint and evasion genes between all TAM from ICB-exposed versus ICB-naive patients. Significance of differential expression ( $q$  value) was determined by two-sided Wilcoxon rank-sum test with Bonferroni FDR correction. Boxplots include centerline, median; box limits, upper and lower quartiles; and whiskers extending at most  $1.5\times$  the interquartile range past upper and lower quartiles.


(G) Violin and boxplots comparing expression distributions of immune checkpoint and evasion genes between all TAM from ICB PR versus ICB SD/PD patients. Significance of differential expression ( $q$  value) was determined by two-sided Wilcoxon rank-sum test with Bonferroni FDR correction. Boxplots include centerline, median; box limits, upper and lower quartiles; and whiskers extending at most  $1.5\times$  the interquartile range past upper and lower quartiles.

\*\*\* $q < 0.001$ , ns: not significant, two-sided Wilcoxon rank-sum test with Bonferroni FDR correction. See also [Figure S4](#), [Table S3](#).

except one with few cancer cells (P912), independent of biopsy site or ICB exposure ([Figure S5A](#)).

We scored cells from the two major clusters for activity of various gene signatures to identify the cellular programs underlying their transcriptional differences. Across different metastatic sites, TP1 cells scored higher for gene sets for kidney morphogenesis, adherens junction assembly, and angiogenesis ([Figure 4C](#)). TP2 cells were characterized by large differences in metabolic programs, with increases in both glycolysis and oxida-

tive phosphorylation, along with concomitant increases in fatty acid metabolism. The simultaneous upregulation of both oxidative phosphorylation and glycolysis genes in TP2 cells was unexpected and points to elevated metabolism in this tumor subpopulation, which may indicate metabolic plasticity permitting opportunistic use of different energetic pathways. The presence of cells in this hybrid metabolic state is consistent with theoretical models that predict such a cell state under high HIF-1 activity, which is well established in RCC, with observations in cell




**Figure 4. Two malignant cell programs with distinct metabolic and immune-reactive characteristics are conserved across biopsy sites**  
 (A) UMAP of malignant cells captured across all lesions, colored and labeled by cluster. Bar plots show cluster proportions grouped by ICB treatment history.  
 (B) Heatmap of scaled normalized expression for cluster-defining genes as determined by two-sided Wilcoxon rank-sum test with Bonferroni FDR correction ( $q < 0.01$ ).  
 (C) Violin and boxplots comparing single-cell signature score distributions between the two dominant malignant cell clusters, partitioned by biopsy site. Significance of differential signature enrichment (p value) was determined by two-sided Wilcoxon rank-sum test. Boxplots include centerline, median; box limits, upper and lower quartiles; and whiskers extending at most 1.5 $\times$  the interquartile range past upper and lower quartiles.  
 (D) GSEA of hallmark interferon- $\gamma$  response and gene ontology antigen presentation and processing via MHC class I signatures in TP1 cells from ICB PR patients compared with ICB SD/PD patients (top) and TP2 cells from ICB PR patients compared with ICB SD/PD patients (bottom).  
 (E) Heatmap of differential expression q values (two-sided Wilcoxon rank-sum test with Bonferroni FDR correction) for immune checkpoint and evasion genes in comparisons of cells within each cluster from ICB-exposed versus ICB-naive patients.  
 (F) Heatmap of differential expression q values (two-sided Wilcoxon rank-sum test with Bonferroni FDR correction) for immune checkpoint and evasion genes in comparisons of cells within each cluster from ICB PR versus ICB SD/PD patients.  
 \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , two-sided Wilcoxon rank-sum test. See also [Figure S5](#), [Table S4](#).

lines linking such plasticity to metastasis (Jia et al., 2019; Wetsten et al., 2017; Yu et al., 2017).

We next examined the potential effects of these cancer cell programs on immune cells in the context of ICB therapy. Comparing ICB responders with non-responders, both cancer cell populations upregulated gene sets associated with interferon- $\gamma$  response and antigen processing on major histocompatibility complex (MHC) class I, indicating a response to the pro-inflammatory microenvironment in responders (Figures 4D and S5B–S5E; Table S4). However, ICB-treated cancer cells also upregulated several T cell checkpoint molecules, with different pat-

terns in the two populations (Figure 4E). TP1 cells robustly upregulated nectin-2 after therapy, while TP2 cells had more moderate increases in expression of several checkpoint molecules. Comparing ICB responders with non-responders, TP2 cells exhibited a more dramatic difference, broadly upregulating both a host of T cell checkpoint molecules and molecules involved in decreasing macrophage inflammation and evading phagocytosis (Figure 4F). We recapitulated our findings in a more homogeneous subset of our cohort (Figures S5F–S5L). In sum, our results suggest complex interactions between the many cell populations in the microenvironment, with the two





**Figure 5. Tumor program signatures are prognostic in the Checkmate 025 RCC cohort and associated with distinct genomic features**

(A) Kaplan-Meier analysis of overall survival (OS) in the Checkmate 025 RCC cohort, with patients separated by high and low TP1 score in bulk RNA-seq.  $p_{\text{log-rank}}$ , log-rank test p value;  $p_{\text{Cox}}$ , p value determined via a multivariate Cox proportional hazard model using TP1 score dichotomized within treatment arm and incorporating age, sex, MSKCC risk group, prior lines of therapy ( $\leq 1$  or  $\geq 2$ ), and days between biopsy collection and start of trial therapy as covariates.

(B) Kaplan-Meier analysis of OS in the Checkmate 025 RCC cohort, with patients separated by high and low immune checkpoint/evasion score in bulk RNA-seq.  $p_{\text{log-rank}}$ , log-rank test p value;  $p_{\text{Cox}}$ , p value determined via a multivariate Cox proportional hazard model using immune checkpoint/evasion score dichotomized within treatment arm and incorporating age, sex, MSKCC risk group, prior lines of therapy ( $\leq 1$  or  $\geq 2$ ), and days between biopsy collection and start of trial therapy as covariates.

(C) Bar plots comparing TP1 and TP2 score between mutant and wild-type samples for commonly mutated genes in the Checkmate 025 RCC cohort. Significance of differential score enrichment (q value) determined by two-sided Wilcoxon rank-sum test with Benjamini-Hochberg FDR correction. Gray dotted line corresponds to  $q = 0.05$ .

(D) Bar plots comparing TP1 and TP2 score between mutant and wild-type samples for common copy number alterations in the Checkmate 025 RCC cohort. Significance of differential score enrichment (q value) determined by two-sided Wilcoxon rank-sum test with Benjamini-Hochberg FDR correction. Gray dotted line corresponds to  $q = 0.05$ .

See also Figure S6, Table S5.

cancer cell populations presenting different immunosuppressive signals to both CD8<sup>+</sup> T cells and TAMs during ICB therapy.

### TP1 cancer expression program associated with improved survival

The differences between TP1 and TP2 cancer cells with respect to kidney differentiation, metabolism, and immunosuppressive signaling prompted us to investigate in a large prospective cohort whether they play different roles in disease progression and resistance to therapy. We generated gene signatures describing TP1 and TP2 and restricted these signatures to cancer-cell-specific genes (Table S5). Having leveraged our scRNA-seq data to generate cancer-cell-specific signatures, we then scored bulk RNA-seq of pre-treatment samples from advanced ccRCC in a randomized clinical trial (Checkmate 025) comparing the mTOR inhibitor everolimus with nivolumab (Table S5) (Braun et al., 2020). We observed an association between pre-treatment TP1 score and significantly improved overall survival only within

patients receiving nivolumab in multivariate analysis, although score levels between radiographic response categories were not significantly different (Figures 5A and S6A–S6C). In a joint analysis including patients from both arms modeling treatment arm, TP1 score, and a treatment-TP1 interaction term, we observed a significant interaction between TP1 score and treatment with nivolumab ( $p = 0.04$ , Cox proportional hazards). These results indicate that the relationship between TP1 score and survival is driven by cancer-immune interactions. There was no significant association between TP2 scores and survival (Figure S6D). However, in nivolumab-treated patients, decreased survival was associated with higher expression of a set of immune checkpoint and evasion genes, almost all of which were significantly upregulated in TP2 cells from ICB responders versus non-responders, albeit these genes are not cancer cell specific (Figures 4F and 5B) ( $p_{\text{Cox}} = 0.017$ ).

To better understand the etiology of these two cancer cell programs, we evaluated whether they were associated with

underlying genomic features. In the Checkmate 025 cohort, we noted an increase in TP1 score in *PBRM1* and *KDM5C* mutant tumors and an increase in TP2 score in tumors harboring 9p21.3 deletions, which were previously associated with ICB resistance (Figures 5C and 5D) (Braun et al., 2020). The association of TP1 score with *PBRM1* mutations and TP2 score with 9p21.3 deletions was corroborated in the TCGA KIRC cohort (Figures S6E and S6F). In ICB-treated Checkmate 025 patients, TP1 score remained significantly associated with increased survival when incorporating *PBRM1* mutation status as a covariate (Figure S6G). In conjunction with the observation of associations with *KDM5C* and copy number alterations, this suggested that TP1 captures transcriptional patterns associated with genomic alterations beyond single gene mutations.

The survival benefit in the Checkmate 025 ICB arm prompted further investigation of interactions between cancer cell subpopulations and immune cells. We examined CIBERSORTx immune cell population abundances inferred in Checkmate 025 (nivolumab arm) using cell-type expression signatures derived from our dataset (Figures S6H and S6I; Table S5) (Newman et al., 2019). In tumors with higher TP1 score, we observed increases in inferred abundance of 4-1BB-Lo CD8<sup>+</sup> T cells, noted earlier for dramatic upregulation of effector molecule expression during ICB therapy and resemblance to progenitor exhausted cells promoting ICB response in melanoma (Figure 2F) (Miller et al., 2019). Although computational inference of abundances of related immune cell populations in bulk cohorts is challenging, these findings support a relationship between TP1 expression programs in cancer cells and survival mediated by cancer-immune cell interactions. Collectively, our observations of distinct tumor subpopulations with different immune cell interactions may help explain the observation in bulk RNA-seq of distinct clusters of RCC, including heterogeneously infiltrated highly angiogenic tumors and non-infiltrated highly metabolic tumors (Şenbabaoglu et al., 2016).

### Cell-cell interactions within the tumor microenvironment

Given observations of *IFNG* upregulation in ICB-exposed 4-1BB-Lo CD8<sup>+</sup> T cells, immune checkpoint and evasion gene upregulation in TAMs from ICB responders, and differentially immunomodulatory cancer cell programs, we hypothesized that the different cell populations participate in a complex cross talk. To identify possible non-cell-autonomous effects, we used CellPhoneDB to identify putative signaling between different cell populations via known receptor-ligand pairs (Figure 6A) (Efremova et al., 2020). Both cancer cell populations were inferred to signal to CD8<sup>+</sup> T cells expressing CD44 via osteopontin (encoded by *SPP1*), an interaction that suppresses T cell activation in mouse models (Klement et al., 2018). Likewise, both cancer cell populations expressed MIF and CD47, signaling to CD74 and SIRP $\alpha$  expressed on TAMs, interactions that promote TAM secretion of growth factors and that inhibit phagocytosis, respectively. However, only TP2 cells were inferred to engage TIM-3 (encoded by *HAVCR2*) expressed on both CD8<sup>+</sup> T cells and TAMs via galectin-9 (encoded by *LGALS9*). Signaling through TIM-3 inhibits CD8<sup>+</sup> cytotoxic cell activity and, in other human cancers, induces TAM secretion of growth factors (Das et al., 2017). In addition, TP2 cells expressed nectin-2, which


binds to the CD8<sup>+</sup> T cell co-inhibitory receptor TIGIT (Yu et al., 2009). Although such an *in silico* approach cannot definitively establish an interaction, it suggested the possibility of complex regulation of both T cells and TAMs by cancer cells.

We additionally observed evidence of interactions between CD8<sup>+</sup> T cells and TAMs. Consistent with upregulation of interferon-response genes in TAMs from ICB responders versus non-responders, CellPhoneDB inferred regulation of TAMs by interferon- $\gamma$  produced by CD8<sup>+</sup> T cells (Figures 3E and 6A). Within on-ICB biopsies from Checkmate 009, normalized *IFNG* levels were robustly correlated with CIBERSORTx-estimated CXCL10-Hi TAM fractions and with an expression signature derived from comparing ICB-exposed to ICB-naive TAMs from our single-cell cohort (Figure 6B; Tables S2 and S3). Within the same samples, we observed concomitant increases in expression of immune checkpoint and evasion genes in samples with higher normalized *IFNG* expression, consistent with immunosuppressive negative feedback loops reported in other cancer types (Figure 6C; Tables S2 and S5) (Abiko et al., 2015; Bellucci et al., 2015; Garcia-Diaz et al., 2017). Indeed, comparing pre- and on-ICB biopsies from the same patients, we observed increases in expression levels of the immune checkpoint and evasion signature and of member genes, including *VSIG4*, *PD-L2*, and *SIGLEC10* (Figure 6D; Tables S2 and S5). Several of these genes are expressed by both cancer cells and TAMs, and their origin cannot be deciphered in bulk transcriptomes, but these comparisons suggest that the tumor microenvironment may adapt to ICB treatment by increasing immunosuppressive gene expression.

### DISCUSSION

To investigate immune system and cancer responses to therapy, we examined single-cell transcriptomes from advanced RCC before or after ICB. A subpopulation of CD8<sup>+</sup> T cells is robustly activated and differentiated toward a terminally exhausted phenotype in responders. These cells have similarities to those described as mediating ICB response in melanoma and may correspond to a population described as the progeny of stem-like CD8<sup>+</sup> T cells in RCC (Jansen et al., 2019; Miller et al., 2019). Among TAMs, we identified a small pro-inflammatory population and multiple others that coherently shift toward a pro-inflammatory phenotype in response to interferon- $\gamma$  signaling in ICB responders. ICB exposure was associated with increases in T cell checkpoint molecule expression and anti-inflammatory signaling, suggesting immune system adaptation that may underlie treatment resistance. Within cancer cells, we uncovered two populations differentiated by expression of pro-angiogenic, kidney differentiation, and metabolic programs. In response to ICB, metabolically plastic and less differentiated TP2 cancer cells upregulated a host of immunosuppressive genes. Whereas cells from both populations were observed across biopsies in our cohort, an increase in the TP1 cancer program was associated with increased survival with ICB, suggesting that differences in cancer-immune cross talk operate between the two populations.

Clinical heterogeneity poses a challenge to our study given the modest biopsy numbers. Almost all ICB-exposed patients had exposure to TKIs, so observed effects may be driven by the



**Figure 6. *IFNG* is associated with pro-inflammatory TAM and immune checkpoint/evasion phenotypes in the Checkmate 009 RCC cohort**

(A) Heatmap of cell-type-specific receptor-ligand interactions inferred by CellPhoneDB. Shown are inferred interactions between malignant cell clusters and all CD8<sup>+</sup> T cells, malignant cell clusters and all TAMs, and all CD8<sup>+</sup> T cells and all TAMs. Circle size indicates significance of interaction and circle color indicates mean expression of receptor and ligand genes for each pair.

(B) Scatterplots of CXCL10-Hi TAM fraction (left) and ICB-exposed TAM signature score (right) versus *IFNG* gene expression normalized by total CD8<sup>+</sup> T cell fraction in bulk RNA-seq of on-ICB samples in the Checkmate 009 RCC cohort. Cell-type fractions were inferred using CIBERSORTx. Pearson coefficient (R) and associated p value are reported for each correlation.

(C) Scatterplots of immune checkpoint/evasion signature score versus *IFNG* expression normalized by total CD8<sup>+</sup> T cell fraction (left) and immune checkpoint/evasion score versus hallmark interferon- $\gamma$  response signature score (right) in bulk RNA-seq of on-ICB samples in the Checkmate 009 RCC cohort. Cell-type fractions were inferred using CIBERSORTx. Pearson coefficient (R) and associated p value are reported for each correlation.

(D) Signature scores for the immune checkpoint/evasion signature and expression values for individual genes in paired pre-/on-ICB bulk RNA-seq samples in the Checkmate 009 RCC cohort. Significance of differential signature enrichment or expression (p value) was determined by paired two-sided Wilcoxon rank-sum test. Boxplots include centerline, median; box limits, upper and lower quartiles; and whiskers extending at most 1.5 $\times$  the interquartile range past upper and lower quartiles.

combination. Nonetheless, as TKI and ICB combination or sequential therapy is the standard of care, our findings remain relevant for future work. RCC most commonly manifests as ccRCC, and our dataset reflects this. Whereas we have explicitly focused on expression programs found across patients, detailed studies of other histologies are needed. We validated our findings in uniformly treated bulk-sequenced clinical trial cohorts, including one with longitudinal pre- and on-ICB biopsies. Nonetheless, bulk RNA-seq is limited by unknown cell-type admixture, so future work should focus on large cohorts of paired ICB-naive and ICB-resistant biopsies using single-cell approaches. Multiplex imaging analyses may elucidate mechanisms of cross talk, which appear pervasive in RCC (Braun et al., 2021). This is particularly pressing given the upregulation of immunosuppressive genes in both TAMs and cancer cells, which may ultimately precipitate resistance.

Our findings highlight the importance of studying immunomodulatory pathways away from the PD-1 axis, including T cell inhibition by VISTA expressed by both TAMs and cancer cells. Targeting the CD47/SIRP $\alpha$  axis with anti-CD47 antibodies, perhaps in conjunction with anti-PD-1 therapy, may promote macrophage phagocytosis of TP2 cells, which upregulate a broad range of immunosuppressive genes in ICB responders. These investigations are urgent now that ICB is a standard of care, and our findings provide a path toward identifying therapeutic targets and combinations to combat treatment resistance.

## STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead contact
  - Materials availability
  - Data and code availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
- **METHOD DETAILS**
  - Somatic mutation and copy number alteration calls
  - Sample collection and dissociation for scRNA-seq
  - scRNA-seq data preprocessing
  - Across-sample integration
  - Visualization, clustering, and identification of cell types
  - Identification of cancer cells
  - Differential expression and gene set level analysis
  - Receptor-ligand interaction inference
  - Bulk RNA-seq and survival analysis
- **QUANTIFICATION AND STATISTICAL ANALYSIS**

## SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.ccell.2021.02.015>.

## ACKNOWLEDGMENTS

We thank the patients who participated in this study. We thank B.C. Miller for thoughtful discussions of this work. This work was supported by the National

Institutes of Health (U01 CA233100 [E.M.V.A.], R01 CA227388 [E.M.V.A.], U2C CA233195 [K.B., A. Regev, E.M.V.A.], T32 GM008313 [M.X.H.], T32 CA009172 [A.K.T.]), the National Science Foundation (GRFP DGE1144152 [M.X.H.]), a Novartis-DDP grant (R.H., E.M.V.A., T.K.C.), a Kure It-AACR grant (E.M.V.A., T.C.), a Dunkin' Donuts Breakthrough Grant (E.M.V.A.), the DF/HCC Kidney Cancer SP0RE (P50CA101942-15 [D.A.B.], T.K.C.), the DOD CDMRP (KC170216 and KC190130 [D.A.B.]), and the DOD Academy of Kidney Cancer Investigators (KC190128 [D.A.B.]). T.K.C. is supported in part by the Kohlberg Chair at Harvard Medical School and the Trust Family, Michael Brigham, and Loker Pinarid Funds for Kidney Cancer Research at DFCl. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the National Science Foundation.

## AUTHOR CONTRIBUTIONS

Conceptualization, K.B., M.X.H., O.R.-R., A. Rotem, A. Regev, T.K.C., and E.M.V.A.; validation, K.B. and M.X.H.; formal analysis, K.B. and M.X.H.; investigation, A.K., S.N., J.W., G.G., M.S.C., T.D., S.V., and A. Rotem; resources, S.L.C., B.A.M., R.H., S.S., and J.L.G.; data curation, Z.B., A.M., L.D., G.B., J.S., A.K.T., and N.I.V.; writing – original draft, K.B., M.X.H., S.V., and E.M.V.A.; writing – reviewing & editing, Z.B., D.A.B., J.L.G., A. Regev, and T.K.C.; visualization, K.B.; supervision, S.S., S.V., O.R.-R., A. Rotem, A. Regev, T.K.C., and E.M.V.A.; project administration, M.X.H., A.M., L.D., G.B., J.S., E.S., M.S., and J.P.; funding acquisition, R.H., A. Regev, T.K.C., and E.M.V.A.

## DECLARATION OF INTERESTS

M.X.H. has consulted for Amplify Medicines and Ikena Oncology. Z.B. reports research support from Bristol-Meyers Squibb (BMS) and Genentech/imCORE unrelated to this study. D.A.B. reports non-financial support from BMS, honoraria from LM Education/Exchange Services, and personal fees from Octane Global, Defined Health, Dedham Group, Adept Field Solutions, Slingshot Insights, Blueprint Partnerships, Charles River Associates, Trinity Group, and Insight Strategy, outside of this work. B.A.M. has consulted for Bayer, Astellas, AstraZeneca, Seattle Genetics, Exelixis, Nektar, Pfizer, Janssen, Genentech, Eisai, and EMD Serono. He received research support to Dana-Farber Cancer Institute from BMS, Calithera, Exelixis, and Seattle Genetics. J.L.G. is a consultant for and/or receives sponsored research support from GlaxoSmithKline (GSK), Array BioPharma, Codagenix, Verseau, Kymera, and Eli Lilly. A. Rotem is an employee of AstraZeneca and an equity holder in NucleAI and Celsius Therapeutics. A. Regev is a founder and equity holder of Celsius Therapeutics, holds equity in Immunitas Therapeutics, and, until August 31, 2020, was an SAB member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov, and Thermo Fisher Scientific; since August 1, 2020, she has been an employee of Genentech. E.M.V.A. reports advisory/consulting with Tango Therapeutics, Genome Medical, Invitae, Monte Rosa, Enara Bio, Manifold Bio, and Janssen; research support from Novartis and BMS; equity in Tango Therapeutics, Genome Medical, Syapse, Manifold Bio, Monte Rosa, and Enara Bio. T.K.C. reports research support/honoraria from, consulting/advisory relationships with, and/or equity stakes in Alexion, Analysis Group, AstraZeneca, Aveo, Bayer, BMS, Calithera, Cerulean, Corvus, Eisai, EMD Serono, Exelixis, F. Hoffmann-La Roche, Foundation Management, Genentech, GSK, Heron Therapeutics, Infinity Pharma, Janssen Oncology, IQVIA, Ipsen, Lilly, Merck, NCCN, Novartis, Peloton, Pfizer, Pionyr, Promethues Labs, Roche, Roche Products Limited, Sanofi/Aventis, Takeda, Tracoon, Surface Oncology, Tempest, Up-to-Date, OncLive, PVI, and MJH Life Sciences; patents filed, royalties, or other intellectual properties related to biomarkers of immune checkpoint blockers; and support from the Dana-Farber/Harvard Cancer Center Kidney SP0RE and Program, the Kohlberg Chair at Harvard Medical School and the Trust Family, Michael Brigham, and Loker Pinarid Funds for Kidney Cancer Research at DFCl.

Received: July 20, 2020

Revised: October 19, 2020

Accepted: February 19, 2021

Published: March 11, 2021

**REFERENCES**

- Abiko, K., Matsumura, N., Hamanishi, J., Horikawa, N., Murakami, R., Yamaguchi, K., Yoshioka, Y., Baba, T., Konishi, I., and Mandai, M. (2015). IFN- $\gamma$  from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. *Br. J. Cancer* *112*, 1501–1509.
- Barkal, A.A., Brewer, R.E., Markovic, M., Kowarsky, M., Barkal, S.A., Zaro, B.W., Krishnan, V., Hatakeyama, J., Dorigo, O., Barkal, L.J., et al. (2019). CD24 signalling through macrophage Siglec-10 is a new target for cancer immunotherapy. *Nature* *572*, 392–396.
- Bell, L.C.K., Pollara, G., Pascoe, M., Tomlinson, G.S., Lehloeny, R.J., Roe, J., Meldau, R., Miller, R.F., Ramsay, A., Chain, B.M., et al. (2016). In vivo molecular dissection of the effects of HIV-1 in active Tuberculosis. *PLoS Pathog.* *12*, e1005469.
- Bellucci, R., Martin, A., Bommarito, D., Wang, K., Hansen, S.H., Freeman, G.J., and Ritz, J. (2015). Interferon- $\gamma$ -induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. *Oncolmmunology* *4*, e1008824.
- Benjamini, Y., and Hochberg, Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J. R. Stat. Soc. B* *57*, 289–300.
- Braun, D.A., Ishii, Y., Walsh, A.M., Van Allen, E.M., Wu, C.J., Shukla, S.A., and Choueiri, T.K. (2019). Clinical validation of PBRM1 alterations as a marker of immune checkpoint inhibitor response in renal cell carcinoma. *JAMA Oncol.* *5*, 1631–1633.
- Braun, D.A., Hou, Y., Bakouny, Z., Ficial, M., Sant' Angelo, M., Forman, J., Ross-Macdonald, P., Berger, A.C., Jegede, O.A., Elagina, L., et al. (2020). Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. *Nat. Med.* *26*, 909–918.
- Braun, D.A., Street, K., Burke, K.P., Cookmeyer, D.L., Denize, T., Pedersen, C.B., Gohil, S.H., Schindler, N., Pomerance, L., Hirsch, L., et al. (2021). Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. *Cancer Cell*, this issue, 632–648.
- Butler, A., Hoffman, P., Smibert, P., Papalexi, E., and Satija, R. (2018). Integrating single-cell transcriptomic data across different conditions, technologies, and species. *Nat. Biotechnol.* *36*, 411–420.
- Canale, F.P., Ramello, M.C., Núñez, N., Furlan, C.L.A., Bossio, S.N., Serrán, M.G., Boari, J.T., Castillo, A.del, Ledesma, M., Sedlik, C., et al. (2018). CD39 expression defines cell exhaustion in tumor-infiltrating CD8<sup>+</sup> T cells. *Cancer Res.* *78*, 115–128.
- Chevrier, S., Levine, J.H., Zanotelli, V.R.T., Silina, K., Schulz, D., Bacac, M., Ries, C.H., Ailles, L., Jewett, M.A.S., Moch, H., et al. (2017). An immune atlas of clear cell renal cell carcinoma. *Cell* *169*, 736–749.e18.
- Choueiri, T.K., Fishman, M.N., Escudier, B., McDermott, D.F., Drake, C.G., Kluger, H., Stadler, W.M., Perez-Gracia, J.L., McNeel, D.G., Curti, B., et al. (2016). Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma. *Clin. Cancer Res.* *22*, 5461–5471.
- Choueiri, T.K., and Motzer, R.J. (2017). Systemic therapy for metastatic renal-cell carcinoma. *N Engl J Med* *376*, 354–366.
- Cibulskis, K., Lawrence, M.S., Carter, S.L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E.S., and Getz, G. (2013). Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. *Nat. Biotechnol.* *31*, 213–219.
- Collin, M., and Bigley, V. (2018). Human dendritic cell subsets: an update. *Immunology* *154*, 3–20.
- Creighton, C.J., Morgan, M., Gunaratne, P.H., Wheeler, D.A., Gibbs, R.A., Gordon Robertson, A., Chu, A., Beroukhir, R., Cibulskis, K., Signoretti, S., et al. (2013). Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature* *499*, 43–49.
- Das, M., Zhu, C., and Kuchroo, V.K. (2017). Tim-3 and its role in regulating anti-tumor immunity. *Immunol. Rev.* *276*, 97–111.
- DeTomaso, D., Jones, M.G., Subramaniam, M., Ashuach, T., Ye, C.J., and Yosef, N. (2019). Functional interpretation of single cell similarity maps. *Nat. Commun.* *10*, 4376.
- Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* *29*, 15–21.
- Duhen, T., Duhen, R., Montler, R., Moses, J., Moudgil, T., de Miranda, N.F., Goodall, C.P., Blair, T.C., Fox, B.A., McDermott, J.E., et al. (2018). Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. *Nat. Commun.* *9*, 2724.
- Efremova, M., Vento-Tormo, M., Teichmann, S.A., and Vento-Tormo, R. (2020). CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes. *Nat. Protoc.* *15*, 1484–1506.
- Frankish, A., Diekhans, M., Ferreira, A.-M., Johnson, R., Jungreis, I., Loveland, J., Mudge, J.M., Sisu, C., Wright, J., Armstrong, J., et al. (2019). GENCODE reference annotation for the human and mouse genomes. *Nucleic Acids Res.* *47*, D766–D773.
- García-Díaz, A., Shin, D.S., Moreno, B.H., Saco, J., Escuin-Ordinas, H., Rodríguez, G.A., Zaretsky, J.M., Sun, L., Hugo, W., Wang, X., et al. (2017). Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. *Cell Rep.* *19*, 1189–1201.
- Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012). Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing (Massachusetts Medical Society).
- Guerriero, J.L. (2018). Macrophages: the road less traveled, changing anti-cancer therapy. *Trends Mol. Med.* *24*, 472–489.
- He, M.X., Cuoco, M.S., Crowdis, J., Bosma-Moody, A., Zhang, Z., Bi, K., Kanodia, A., Su, M.-J., Ku, S.-Y., García, M.M., et al. (2021). Transcriptional mediators of treatment resistance in lethal prostate cancer. *Nat. Med.* <https://doi.org/10.1038/s41591-021-01244-6>.
- Horisberger, M.A., Staeheli, P., and Haller, O. (1983). Interferon induces a unique protein in mouse cells bearing a gene for resistance to influenza virus. *PNAS* *80*, 1910–1914.
- Hsieh, J.J., Purdue, M.P., Signoretti, S., Swanton, C., Albiges, L., Schmidinger, M., Heng, D.Y., Larkin, J., and Ficarra, V. (2017). Renal cell carcinoma. *Nat. Rev. Dis. Primers* *3*, 1–19.
- Jansen, C.S., Prokhnevskaya, N., Master, V.A., Sanda, M.G., Carlisle, J.W., Bilen, M.A., Cardenas, M., Wilkinson, S., Lake, R., Sowalsky, A.G., et al. (2019). An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. *Nature* *576*, 465–470.
- Jia, D., Lu, M., Jung, K.H., Park, J.H., Yu, L., Onuchic, J.N., Kaiparettu, B.A., and Levine, H. (2019). Elucidating cancer metabolic plasticity by coupling gene regulation with metabolic pathways. *Proc. Natl. Acad. Sci. U S A* *116*, 3909–3918.
- Klement, J.D., Paschall, A.V., Redd, P.S., Ibrahim, M.L., Lu, C., Yang, D., Celis, E., Abrams, S.I., Ozato, K., and Liu, K. (2018). An osteopontin/CD44 immune checkpoint controls CD8<sup>+</sup> T cell activation and tumor immune evasion. *J. Clin. Invest.* *128*, 5549–5560.
- Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with Burrows–Wheeler transform. *Bioinformatics* *25*, 1754–1760.
- Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J.P., and Tamayo, P. (2015). The molecular signatures database Hallmark gene set collection. *Cell Syst.* *1*, 417–425.
- Lines, J.L., Sempere, L.F., Wang, L., Pantazi, E., Mak, J., O'Connell, S., Ceeraz, S., Suriawinata, A.A., Yan, S., Ernstoff, M.S., et al. (2014). VISTA is an immune checkpoint molecule for human T cells. *Cancer Res.* *74*, 1924–1932.
- Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., and Allavena, P. (2017). Tumour-associated macrophages as treatment targets in oncology. *Nat. Rev. Clin. Oncol.* *14*, 399–416.
- McDermott, D.F., Huseni, M.A., Atkins, M.B., Motzer, R.J., Rini, B.I., Escudier, B., Fong, L., Joseph, R.W., Pal, S.K., Reeves, J.A., et al. (2018). Clinical activity

- and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. *Nat. Med.* **24**, 749–757.
- Miao, D., Margolis, C.A., Gao, W., Voss, M.H., Li, W., Martini, D.J., Norton, C., Bossé, D., Wankowicz, S.M., Cullen, D., et al. (2018). Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. *Science* **359**, 801–806.
- Miller, B.C., Sen, D.R., Al Aboosy, R., Bi, K., Virkud, Y.V., LaFleur, M.W., Yates, K.B., Lako, A., Felt, K., Naik, G.S., et al. (2019). Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. *Nat. Immunol.* **20**, 326–336.
- Motzer, R.J., Hutson, T.E., McCann, L., Deen, K., and Choueiri, T.K. (2014). Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. *N Engl J Med* **370** (18), 1769–1770.
- Motzer, R.J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M.T., Venugopal, B., Kollmannsberger, C., Negrier, S., Uemura, M., et al. (2019). Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N Engl J Med* **380**, 1103–1115.
- Newman, A.M., Steen, C.B., Liu, C.L., Gentles, A.J., Chaudhuri, A.A., Scherer, F., Khodadoust, M.S., Esfahani, M.S., Luca, B.A., Steiner, D., et al. (2019). Determining cell type abundance and expression from bulk tissues with digital cytometry. *Nat. Biotechnol.* **37**, 773–782.
- Patro, R., Duggal, G., Love, M.I., Irizarry, R.A., and Kingsford, C. (2017). Salmon: fast and bias-aware quantification of transcript expression using dual-phase inference. *Nat. Methods* **14**, 417–419.
- Puig-Kröger, A., Sierra-Filardi, E., Domínguez-Soto, A., Samaniego, R., Corcuera, M.T., Gómez-Aguado, F., Ratnam, M., Sánchez-Mateos, P., and Corbí, A.L. (2009). Folate receptor  $\beta$  is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. *Cancer Res.* **69**, 9395–9403.
- Ricketts, C.J., De Cubas, A.A., Fan, H., Smith, C.C., Lang, M., Reznik, E., Bowlby, R., Gibb, E.A., Akbani, R., Beroukhi, R., et al. (2018). The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. *Cell Rep.* **23**, 313–326.e5.
- Rini, B.I., Plimack, E.R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019). Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med* **380**, 1116–1127.
- Sade-Feldman, M., Yizhak, K., Bjorgaard, S.L., Ray, J.P., de Boer, C.G., Jenkins, R.W., Lieb, D.J., Chen, J.H., Frederick, D.T., Barzily-Rokni, M., et al. (2018). Defining T cell states associated with response to checkpoint immunotherapy in melanoma. *Cell* **175**, 998–1013.e20.
- Scott, A.C., Dündar, F., Zumbo, P., Chandran, S.S., Klebanoff, C.A., Shakiba, M., Trivedi, P., Menocal, L., Appleby, H., Camara, S., et al. (2019). TOX is a critical regulator of tumour-specific T cell differentiation. *Nature* **571**, 270–274.
- Şenbabaoglu, Y., Gejman, R.S., Winer, A.G., Liu, M., Van Allen, E.M., de Velasco, G., Miao, D., Ostrovskaya, I., Drill, E., Luna, A., et al. (2016). Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. *Genome Biol.* **17**, 231.
- Sergushichev, A.A. (2016). An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation. *BioRxiv*, 060012.
- Shen, R., and Seshan, V.E. (2016). FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. *Nucleic Acids Res.* **44**, e131.
- Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W.M., Hao, Y., Stoekius, M., Smibert, P., and Satija, R. (2019). Comprehensive integration of single-cell data. *Cell* **177**, 1888–1902.e21.
- Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *PNAS* **102**, 15545–15550.
- Thommen, D.S., and Schumacher, T.N. (2018). T cell dysfunction in cancer. *Cancer Cell* **33**, 547–562.
- Turajlic, S., Xu, H., Litchfield, K., Rowan, A., Chambers, T., Lopez, J.I., Nicol, D., O'Brien, T., Larkin, J., Horswell, S., et al. (2018). Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. *Cell* **173**, 581–594.e12.
- Vogt, L., Schmitz, N., Kurrer, M.O., Bauer, M., Hinton, H.I., Behnke, S., Gatto, D., Sebbel, P., Beerli, R.R., Sonderegger, I., et al. (2006). VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. *J. Clin. Invest.* **116**, 2817–2826.
- Wang, N., Liang, H., and Zen, K. (2014). Molecular mechanisms that influence the macrophage M1–M2 polarization balance. *Front Immunol.* **5**, 614.
- Wettersten, H.I., Aboud, O.A., Lara, P.N., and Weiss, R.H. (2017). Metabolic reprogramming in clear cell renal cell carcinoma. *Nat. Rev. Nephrol.* **13**, 410–419.
- Wolff, M., Kuball, J., Ho, W.Y., Nguyen, H., Manley, T.J., Bleakley, M., and Greenberg, P.D. (2007). Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. *Blood* **110**, 201–210.
- Wolock, S.L., Lopez, R., and Klein, A.M. (2019). Scrublet: computational identification of cell doublets in single-cell transcriptomic data. *Cell Syst.* **8**, 281–291.e9.
- Young, M.D., and Behjati, S. (2020). SoupX removes ambient RNA contamination from droplet based single-cell RNA sequencing data. *BioRxiv*, 303727.
- Young, M.D., Mitchell, T.J., Braga, F.A.V., Tran, M.G.B., Stewart, B.J., Ferdinand, J.R., Collord, G., Botting, R.A., Popescu, D.-M., Loudon, K.W., et al. (2018). Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors. *Science* **361**, 594–599.
- Yu, L., Lu, M., Jia, D., Ma, J., Ben-Jacob, E., Levine, H., Kaiparettu, B.A., and Onuchic, J.N. (2017). Modeling the genetic regulation of cancer metabolism: interplay between glycolysis and oxidative phosphorylation. *Cancer Res.* **77**, 1564–1574.
- Yu, X., Harden, K., Gonzalez, L.C., Francesco, M., Chiang, E., Irving, B., Tom, I., Ivelja, S., Refino, C.J., Clark, H., et al. (2009). The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. *Nat. Immunol.* **10**, 48–57.
- Zhou, L., Zhuo, H., Ouyang, H., Liu, Y., Yuan, F., Sun, L., Liu, F., and Liu, H. (2017). Glycoprotein non-metastatic melanoma protein b (Gpnmb) is highly expressed in macrophages of acute injured kidney and promotes M2 macrophages polarization. *Cell. Immunol.* **316**, 53–60.

## STAR★METHODS

### KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<b>Biological samples</b>		
Renal cell carcinoma patient samples	This paper	N/A
<b>Chemicals, peptides, and recombinant proteins</b>		
Medium 199 with Hank's salts	ThermoFisher Scientific	#12350039
Medium 199 with Earle's salts	Sigma	#M4530
Hank's Balanced Salt Solution	ThermoFisher Scientific	#14170120
5 mM CaCl <sub>2</sub>	Sigma	#10043524
100 μg/mL Collagenase Type 4	Worthington Biochemical Corporation	#LS004186
0.75 u/mL Dispase	StemCell Technologies	#7913
10 μg/mL DNase I	StemCell Technologies	#07900
Accumax	Sigma-Aldrich	#A7089
ACK Lysing Buffer	ThermoFisher Scientific	#10010-23
PBS with 0.4% BSA	Ambion	#AM2616
Trypan blue	Sigma	#T8154
Viahance	BioPAL	#CP-50VQ02
10x Genomics Chromium Single Cell 3' (v2 Chemistry) reagents	10x Genomics	#PN-120237 #PN-120236
<b>Critical commercial assays</b>		
10x Genomics Chromium Single Cell 3' (v2 Chemistry)	10x Genomics	<a href="https://support.10xgenomics.com/single-cell-gene-expression/library-prep/doc/technical-note-assay-scheme-and-configuration-of-chromium-single-cell-3-v2-libraries">https://support.10xgenomics.com/single-cell-gene-expression/library-prep/doc/technical-note-assay-scheme-and-configuration-of-chromium-single-cell-3-v2-libraries</a>
<b>Deposited data</b>		
Raw and processed single cell RNA-seq data	This paper	dbGaP: phs002065.v1.p1 Single Cell Portal: <a href="https://singlecell.broadinstitute.org/single_cell/study/SCP1288/tumor-and-immune-reprogramming-during-immunotherapy-in-advanced-renal-cell-carcinoma#study-summary">https://singlecell.broadinstitute.org/single_cell/study/SCP1288/tumor-and-immune-reprogramming-during-immunotherapy-in-advanced-renal-cell-carcinoma#study-summary</a>
Progenitor (CD8_G) and terminally exhausted (CD8_B) transcriptional signatures	<a href="#">Sade-Feldman et al., 2018</a>	GEO: GSE12057
Checkmate 009 raw and processed bulk RNA-seq data	<a href="#">Miao et al., 2018</a> . This paper	dbGaP: phs001493
Checkmate 025 normalized bulk RNA-seq, clinical, and mutational data	<a href="#">Braun et al., 2020</a>	EGA: EGAS00001004290, EGAS00001004291, EGAS00001004292
TCGA KIRC normalized bulk RNA-seq, clinical, and mutational data	Firebrowse cBioPortal <a href="#">Ricketts et al., 2018</a>	<a href="http://firebrowse.org/:illuminahisq_maseqv2-RSEM_genes_normalized,gdac.broadinstitute.org_KIRC-TP.CopyNumber_Gistic2.Level_4.2016012800.0.0">http://firebrowse.org/:illuminahisq_maseqv2-RSEM_genes_normalized,gdac.broadinstitute.org_KIRC-TP.CopyNumber_Gistic2.Level_4.2016012800.0.0</a> cBioPortal: <a href="https://www.cbioportal.org/study/clinicalData?id=kirc_tcga">https://www.cbioportal.org/study/clinicalData?id=kirc_tcga</a> <a href="https://gdc.cancer.gov/">https://gdc.cancer.gov/</a>
<b>Software and algorithms</b>		
BWA v0.5.9	<a href="#">Li and Durbin, 2009</a>	<a href="http://bio-bwa.sourceforge.net/">http://bio-bwa.sourceforge.net/</a>
MuTect	<a href="#">Cibulskis et al., 2013</a>	<a href="https://github.com/broadinstitute/mutect">https://github.com/broadinstitute/mutect</a>
FACETS	<a href="#">Shen and Seshan, 2016</a>	<a href="https://github.com/vanallenlab/facets">https://github.com/vanallenlab/facets</a>

(Continued on next page)

**Continued**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
10x Cell Ranger analysis pipeline v3.1	10X Genomics	<a href="https://support.10xgenomics.com/single-cell-gene-expression/software/pipelines/3.1/what-is-cell-ranger">https://support.10xgenomics.com/single-cell-gene-expression/software/pipelines/3.1/what-is-cell-ranger</a>
Scrublet python package	Wolock et al., 2019	<a href="https://github.com/AllonKleinLab/scrublet">https://github.com/AllonKleinLab/scrublet</a>
SoupX R package v1.2.2	Young and Behjati, 2020	<a href="https://github.com/constantAmateur/SoupX">https://github.com/constantAmateur/SoupX</a>
Seurat R package v3.1.5	Butler et al., 2018	<a href="https://satijalab.org/seurat/">https://satijalab.org/seurat/</a>
InferCNV	<a href="https://github.com/broadinstitute/inferCNV">https://github.com/broadinstitute/inferCNV</a>	<a href="https://github.com/broadinstitute/inferCNV">https://github.com/broadinstitute/inferCNV</a>
fgsea v1.10.1 R package	Sergushichev, 2016	<a href="https://bioconductor.org/packages/release/bioc/html/fgsea.html">https://bioconductor.org/packages/release/bioc/html/fgsea.html</a>
VISION v2.0.0 R package	DeTomaso et al., 2019	<a href="https://github.com/YosefLab/VISION">https://github.com/YosefLab/VISION</a>
CellPhoneDB python package	Efremova et al., 2020	<a href="https://github.com/Teichlab/cellphonedb">https://github.com/Teichlab/cellphonedb</a>
STAR v2.7.0	Dobin et al., 2013	<a href="https://github.com/alexdobin/STAR">https://github.com/alexdobin/STAR</a>
salmon v0.14.1	Patro et al., 2017	<a href="https://github.com/COMBINE-lab/salmon/releases">https://github.com/COMBINE-lab/salmon/releases</a>
survminer v0.4.6 R package	<a href="https://github.com/kassambara/survminer/releases">https://github.com/kassambara/survminer/releases</a>	<a href="https://github.com/kassambara/survminer/releases">https://github.com/kassambara/survminer/releases</a>
survival v3.1.7 R package	<a href="https://cran.r-project.org/web/packages/survival/index.html">https://cran.r-project.org/web/packages/survival/index.html</a>	<a href="https://cran.r-project.org/web/packages/survival/index.html">https://cran.r-project.org/web/packages/survival/index.html</a>
lifelines v0.23.9 python package	<a href="https://pypi.org/project/lifelines/">https://pypi.org/project/lifelines/</a>	<a href="https://pypi.org/project/lifelines/">https://pypi.org/project/lifelines/</a>
CIBERSORTx	Newman et al., 2019	<a href="https://cibersortx.stanford.edu/runcibersortx.php">https://cibersortx.stanford.edu/runcibersortx.php</a>
R v3.6.0	<a href="https://www.r-project.org/">https://www.r-project.org/</a>	<a href="https://www.r-project.org/">https://www.r-project.org/</a>

**RESOURCE AVAILABILITY**

**Lead contact**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Eliezer M. Van Allen ([eliezerm\\_vanallen@dfci.harvard.edu](mailto:eliezerm_vanallen@dfci.harvard.edu)).

**Materials availability**

This study did not generate new unique reagents.

**Data and code availability**

Raw single cell RNA-seq and bulk whole exome sequencing data are deposited to dbGaP: phs002065.v1.p1. Processed single cell RNA-Seq data can also be accessed via the Single Cell Portal ([https://singlecell.broadinstitute.org/single\\_cell/study/SCP1288/tumor-and-immune-reprogramming-during-immunotherapy-in-advanced-renal-cell-carcinoma#study-summary](https://singlecell.broadinstitute.org/single_cell/study/SCP1288/tumor-and-immune-reprogramming-during-immunotherapy-in-advanced-renal-cell-carcinoma#study-summary)). Code used for all processing and analysis is available upon request.

Transcriptional signatures for progenitor and terminally exhausted CD8<sup>+</sup> T cells (CD8\_G and CD8\_B, respectively) were obtained from published results (Sade-Feldman et al., 2018) (GEO: GSE120575). For the Checkmate 009 cohort, raw bulk RNA-seq data were obtained from published results (Miao et al., 2018) (dbGaP: phs001493). For the Checkmate 025 cohort, normalized bulk RNA-seq, clinical, and mutational data were obtained from published results (Braun et al., 2020) (European Genome-Phenome Archive: EGAS00001004290, EGAS00001004291, EGAS00001004292). For the TCGA clear cell renal cell carcinoma (KIRC) cohort, normalized bulk RNA-seq data were obtained from Firebrowse (<http://firebrowse.org/>, [illuminahisec\\_rnaseqv2-RSEM\\_genes\\_normalized](https://firebrowse.org/illuminahisec_rnaseqv2-RSEM_genes_normalized)). Clinical data were downloaded from the cBioPortal ([https://www.cbioportal.org/study/clinicalData?id=kirc\\_tcga](https://www.cbioportal.org/study/clinicalData?id=kirc_tcga)). Somatic mutation data were obtained from published results (Ricketts et al., 2018) (<https://gdc.cancer.gov/>). GISTIC2 results describing amplification and deletion events in TCGA KIRC were downloaded from Firebrowse (<http://firebrowse.org/>, [gdc.broadinstitute.org\\_KIRC-TP.CopyNumber\\_Gistic2.Level\\_4.2016012800.0.0](https://gdc.broadinstitute.org_KIRC-TP.CopyNumber_Gistic2.Level_4.2016012800.0.0)).

**EXPERIMENTAL MODEL AND SUBJECT DETAILS**

Human patient samples were collected with written informed consent and ethics approval by the Dana-Farber Cancer Institute Institutional Review Board under protocol no. 15-349. Patient metadata, including age at diagnosis, sex, treatment regimen, clinical response, sample biopsy site, histological grade, and disease stage, are provided as Table S1.



## METHOD DETAILS

### Somatic mutation and copy number alteration calls

Where available, additional tissue was used for whole exome sequencing (samples P55, P915, P913, P906, P76) or panel sequencing via OncoPanel (sample P90), with downstream bioinformatic analyses as previously described (He et al., 2021). Briefly, exome capture was performed using Illumina's Rapid Capture Exome Kit, reads were aligned using BWA v0.5.9 (Li and Durbin, 2009), somatic mutation calling was performed using MuTect (Cibulskis et al., 2013), and copy number alterations were called using FACETS (Shen and Seshan, 2016).

### Sample collection and dissociation for scRNA-seq

Single-cell suspensions for single-cell RNA-seq were obtained by mechanical and enzymatic dissociation. Tumor tissue was collected and transported in Medium 199 with Hank's salts (ThermoFisher Scientific #12350039) (samples P912, P913, P915, P916) or Medium 199 with Earle's salts (Sigma #M4530) (other samples) on ice. Enzymatic dissociation mix consisted of calcium- and magnesium-free Hank's Balanced Salt Solution (ThermoFisher Scientific #14170120) with 5 mM CaCl<sub>2</sub> (Sigma #10043524), 100 µg/mL Collagenase Type 4 (Worthington Biochemical Corporation #LS004186), 0.75 u/mL Dispase (StemCell Technologies #7913), and 10 µg/mL DNase I (StemCell Technologies #07900) for most samples (P906, P912, P913, P915, P916). For samples P90 and P55, dissociation mix composition was similar with the exception that Dispase was used at a concentration of 1.125 u/mL. For sample P76, Accumax was used instead (Sigma-Aldrich #A7089). In all cases, the sample was first minced into pieces smaller than 0.5 mm in cold enzymatic dissociation mix using scalpels or spring scissors. The resulting tissue suspension was then incubated for a total of 20 min at 37°C with rotation, interrupted briefly by additional mincing or pipetting after 10 min (samples P906, P912, P913, P915, P916), or for 10 min at 37°C (P90, P55) or room temperature (P76), whereas subsequent steps were carried out at 4°C or on ice. When necessary, additional pipetting was used to complete the dissociation and residual tissue fragments were strained using a 100 µm cell strainer.

Cells were then centrifuged at 580g for 5 min, or using a brief centrifugation (8 sec with centrifugal force ramping up to but not exceeding 11,000 g) to minimize cell loss, and the resulting cell pellet was resuspended in ACK Lysing Buffer (ThermoFisher Scientific #A1049201) to lyse red blood cells. After 1 min incubation on ice, red blood cell lysis was stopped by addition of calcium- and magnesium-free PBS (ThermoFisher Scientific #10010-23) followed by centrifugation. If the resulting pellet appeared bloody, red blood cell lysis was repeated without exceeding 3 min incubation in total. Following red blood cell removal, cells were resuspended in calcium- and magnesium-free PBS with 0.4% BSA (Ambion #AM2616). Cell viability and the presence of cell clumps or debris were then assessed using a hemocytometer after mixing cells with Trypan blue (Sigma #T8154). Based on this assessment, samples P90 and P55 were centrifuged at low speed (200g for 5min) to remove debris, and dead cells were removed from samples P76 and P55 using Viahance (BioPAL #CP-50VQ02). All samples had viability greater than 58%, and 5,000–8,000 viable cells in PBS with 0.4% BSA were loaded per channel of the 10x Genomics Chromium platform using Single Cell 3' (v2 Chemistry) reagents (10x Genomics #PN-120237 and #PN-120236).

### scRNA-seq data preprocessing

scRNA-seq samples were sequenced on an Illumina HiSeq X sequencer. Demultiplexing of sequencing results, barcode processing, read alignment, and UMI counting were performed using the 10x Cell Ranger analysis pipeline v3.1. Reads were aligned to the human genome reference b37 with the GENCODE 30 annotation lifted over to GRCh37 (Frankish et al., 2019). Confidently mapped, non-PCR duplicate reads were counted to generate a gene-barcode matrix for each sample with barcodes filtered to exclude low RNA content droplets.

To exclude data from droplets containing more than one cell, doublet detection and removal were performed on gene-barcode matrices using Scrublet (Wolock et al., 2019). An expected doublet rate parameter of 0.06 was used, and doublet score thresholds were chosen manually to divide putative singlet and neotypic doublet modes in the score distribution. Predicted doublets were then removed from gene-barcode matrices.

To abrogate sample-to-sample differences driven by the ambient RNA profile present in all droplets prepared from a given single-cell suspension, we performed an ambient RNA decontamination step using R package SoupX v1.2.2 (Young and Behjati, 2020). For each sample, an ambient RNA profile was determined from an unfiltered gene-barcode matrix provided by the Cell Ranger pipeline which included low RNA containing droplets. Three classes of genes exhibiting high cell type specificity and bimodality within the samples of our cohort (immunoglobulin, hemoglobin, and macrophage-associated genes such as *APOE* and *C1QA*) were used to estimate per-cell contamination fractions. The ambient RNA profile was then subtracted proportionately from cells of the original gene-barcode matrix. These cleaned gene-barcode matrices were used for all downstream analysis. Further QC, feature selection, dimension reduction, unsupervised clustering, and differential expression analyses were performed using the Seurat R package v3.1.5 (Butler et al., 2018).

### Across-sample integration

Prior to across-sample integration, cells with fewer than 200 genes detected or more than 25% of counts attributed to mitochondrially-encoded transcripts were removed. Genes detected in fewer than three cells across all samples were also excluded. Each gene expression measurement was normalized by total expression in the corresponding cell and multiplied by a scaling factor of 10,000,

then  $\log_2$ -transformed (default Seurat approach). To adjust for technical and biological sources of variation between samples, the standard anchor-based workflow for dataset integration in Seurat was used (Stuart et al., 2019). 10,000 variable features for CCA (canonical correlation analysis) were chosen based on stabilized variance, and integration anchors were identified using the first 30 reduced dimensions. The resulting merged dataset included 34,326 cells and 32,718 detected genes across the eight samples of the cohort. Integration-transformed expression values were used only for dimension reduction and clustering. The original  $\log$ -normalized expression values were used for all differential expression and gene set level analyses.

### Visualization, clustering, and identification of cell types

Principal components analysis (PCA) was performed on the integration-transformed expression matrix, and the first 50 principal components were used for Louvain clustering of cells with a resolution parameter of 0.5. Uniform manifold approximation and projection (UMAP) was performed on the same PCs with 100 nearest neighbors for visualization in two dimensions. To classify cells into broad cell types, differential expression analysis was performed comparing cells of each Louvain cluster to all other clusters using a two-sided Wilcoxon rank-sum test with Bonferroni FDR correction ( $q < 0.01$  considered significant) (Figure S1A). These initial clusters were then merged into lymphoid, myeloid, normal tissue, and putative tumor lineages based on expression of differential marker genes. To identify immune cell types at a high resolution, lymphoid and myeloid cells were re-clustered and re-projected separately using 30 PCs for Louvain clustering and UMAP, with the same differential expression analysis applied to annotate cell type. Further iterations of re-clustering (30 PCs, resolution parameters ranging from 0.15–0.5) were performed within larger cell types, including CD8<sup>+</sup> T cells, T-Helper cells, NK cells, and tumor associated macrophages to identify cell subtypes and states with clearly distinct differential expression profiles.

### Identification of cancer cells

Malignant cells were identified using inferred CNV profiles and cluster-level marker gene expression. We first projected and clustered all cells from each sample separately to identify *PTPRC*<sup>+</sup> and *PTPRC*<sup>-</sup> clusters. We then performed InferCNV (<https://github.com/broadinstitute/inferCNV>) within each sample, using *PTPRC*<sup>+</sup> clusters as reference groups and *PTPRC*<sup>-</sup> clusters as observation groups (Figure S1B). Malignant clusters were identified based on established copy number features of RCC histologies. For clear cell RCC samples, clusters with chromosome 3p loss were called as malignant; for the single papillary RCC sample profiled in the cohort, clusters with gains in chromosomes 7 and 17 were called as malignant. Differential expression analysis showed that observation clusters without distinct CNAs exhibited clear expression patterns associated with fibroblasts or endothelial cells.

These InferCNV results were then cross-referenced with our gene expression marker-based lineage calls. In the fully integrated dataset, Louvain clusters 3, 4, 6, 17, and 21 were identified as putatively malignant based on significant differential expression of *CA9*, *CA12*, *NDUFA4L2*, *VCAM1*, or *VEGFA*. Cells in these clusters constituted 99.38% of cells labelled via InferCNV as malignant. Cancer cells were definitively called as the overlap between these clusters and the set of cells identified as malignant based on copy number profile with InferCNV.

### Differential expression and gene set level analysis

Differential expression analysis comparing cells from treatment exposure or response groups was performed using a two-sided Wilcoxon rank-sum test with Bonferroni FDR correction. Preranked gene set enrichment analysis (GSEA) was performed using the *fgsea* v1.10.1 R package (Sergushichev, 2016; Subramanian et al., 2005). For a given pairwise GSEA comparison, the  $\log_2$ (fold-change) of the average expression between groups was used as a ranking metric. GSEA was performed using Hallmark, KEGG, and GO Biological Process gene sets from v6.2 of the MSigDB repository or select gene sets curated from literature (Bell et al., 2016; Liberzon et al., 2015; McDermott et al., 2018). Gene sets with  $p < 0.05$  and FDR  $< 0.25$  were considered significant.

Single cell signature scoring was performed using the VISION v2.0.0 R package (DeTomaso et al., 2019). Differential signature score enrichment between groups was determined using a two-sided Wilcoxon rank-sum test with Benjamini-Hochberg FDR correction (Benjamini and Hochberg, 1995). VISION scoring was performed using the same MSigDB gene sets cited above. CD8<sup>+</sup> T cells with a progenitor exhausted signature score  $> 0.75$  and a terminally exhausted signature score  $< 2.5$  were called as Progenitor Exhausted Cells, and CD8<sup>+</sup> T cells with a progenitor exhausted signature score  $< 0.75$  and a terminally exhausted signature score  $> 2.5$  were called as Terminally Exhausted Cells.

### Receptor-ligand interaction inference

Inference of receptor-ligand interactions was performed using the CellPhoneDB Python library (Efremova et al., 2020). The algorithm was run on  $\log$ -normalized expression values for tumor cells, tumor-associated macrophages, and CD8<sup>+</sup> T cells with default parameters and no subsampling.

### Bulk RNA-seq and survival analysis

To obtain an ICB-exposed 41BB-Lo CD8<sup>+</sup> T cell signature for projection into bulk RNA-Seq, genes significantly upregulated in 41BB-Lo CD8<sup>+</sup> T cells from ICB-exposed patients relative to those from ICB-naive patients (with  $q < 0.01$ ,  $\log_2$ (fold-change)  $> 0.25$ ) were restricted to lymphoid-specific genes. Lymphoid-specific genes were defined as the intersection between genes expressed in  $< 5\%$  of tumor, myeloid, or normal tissue cells and genes with at least 10% greater expression in lymphoid cells.

To obtain an ICB-exposed TAM signature, genes significantly upregulated in all ICB-exposed TAM (aggregated across the five subsets described) relative to all ICB-naive TAM (with  $q < 0.01$ ,  $\log_2(\text{fold-change}) > 0.25$ ) were restricted to myeloid-specific genes. Myeloid-specific genes were defined as the intersection between genes expressed in  $<5\%$  of tumor, lymphoid, or normal tissue cells and genes with at least 10% greater expression in myeloid cells.

To obtain TP1 and TP2 signatures, genes differentially expressed between TP1 and TP2 cells (with  $q < 0.01$ ,  $\log_2(\text{fold-change}) > 0.5$  or  $< -0.5$ ) were restricted to tumor-specific genes. Tumor-specific genes were defined as the intersection between genes expressed in  $<5\%$  of myeloid, lymphoid, or normal tissue cells and genes with at least 10% greater expression in tumor cells.

We defined a curated Immune Checkpoint/Evasion signature as a set of putatively immunoregulatory genes observed as upregulated in TAM and/or tumor cells from ICB-exposed and ICB-responder lesions. This signature comprised the following genes: *VSI1R*, *VSI1G4*, *LGALS9*, *CD274* (PD-L1), *PDCD1LG2*, *SIGLEC10*, *NECTIN2*, *CD47*, and *MIF*.

Bulk RNA-seq from the Checkmate 009 cohort were aligned to human reference genome b37 and the GENCODE 30 GRCh37 lift-over transcriptome reference using STAR v2.7.0, and TPM quantification was performed with salmon v0.14.1 (Choueiri et al., 2016; Dobin et al., 2013; Frankish et al., 2019; Miao et al., 2018; Patro et al., 2017).

Signature scoring of all bulk RNA-seq samples was performed using the VISION R package (DeTomaso et al., 2019). Significance of differences in OS between samples stratified by signature score were determined via Kaplan-Meier analysis, log-rank tests, and multivariate Cox regression analysis using the survminer v0.4.6 and survival v3.1.7 R packages and the lifelines v0.23.9 Python package. In the Checkmate 025 cohort, multivariate analyses of each arm separately incorporated TP1, TP2, or Immune Checkpoint/Evasion score dichotomized within each arm in addition to patient age, sex, MSKCC risk group, prior lines of therapy ( $\leq 1$  or  $\geq 2$ ), and days between biopsy collection and start of trial therapy as covariates. For the joint analysis of both arms, the model included continuous TP1 score, treatment arm (1 in nivolumab, 0 if everolimus), treatment arm\*TP1 score, patient age, sex, MSKCC risk group, prior lines of therapy ( $\leq 1$  or  $\geq 2$ ), and days between biopsy collection and start of trial therapy. In TCGA KIRC and Checkmate 025 cohorts, comparisons of signature scores between mutant and wild-type tumors, or between ICB response groups, were performed using a two-sided two-sided Wilcoxon rank-sum test with Benjamini-Hochberg FDR correction (Benjamini and Hochberg, 1995). For comparisons of signature scores between mutant and wild-type samples, only mutations with predicted high impact Ensembl Sequence Ontology were considered. In the Checkmate 009 cohort, comparisons of signature scores or TPM between matched pre/on-ICB samples were performed using a paired two-sided two-sided Wilcoxon rank-sum test.

To generate a CIBERSORTx signature matrix using immune cell types from our single cell cohort, we ran the Create Signature Matrix module (<https://cibersortx.stanford.edu/runcibersortx.php>) with the log-normalized expression matrix from our dataset restricted to immune populations of interest supplied as a reference matrix (Newman et al., 2019). We used a Min. Expression parameter of 0.05 and a Min. Barcode Genes parameter of 100, with all other parameters set to default. Using the resulting signature matrix, CIBERSORTx deconvolution was performed on the bulk RNA-seq cohorts in relative mode with S-mode batch correction and quantile normalization disabled. Comparisons of inferred immune population frequencies between samples grouped by signature score were performed using a two-sided Wilcoxon rank-sum test with Benjamini-Hochberg FDR correction (Benjamini and Hochberg, 1995).

## QUANTIFICATION AND STATISTICAL ANALYSIS

All statistical analyses were performed using R (version 3.6.0). For differential expression analysis between groups of cells, a two-sided Wilcoxon rank-sum test with Bonferroni FDR correction was used. For comparisons of signature scores or CIBERSORTx-inferred immune fractions between groups of cells or bulk RNA-Seq samples, a two-sided Wilcoxon rank-sum test with Benjamini-Hochberg FDR correction was used. For survival analysis of bulk RNA-Seq samples stratified by signature score, significance of OS difference was determined using a log-rank test and multivariate Cox proportional hazards model. Descriptions of statistical tests performed for each individual analysis are provided in Figure legends and Method Details.


## Supplemental information

### Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma


Kevin Bi, Meng Xiao He, Ziad Bakouny, Abhay Kanodia, Sara Napolitano, Jingyi Wu, Grace Grimaldi, David A. Braun, Michael S. Cuoco, Angie Mayorga, Laura DelloStritto, Gabrielle Bouchard, John Steinharter, Alok K. Tewari, Natalie I. Vokes, Erin Shannon, Maxine Sun, Jihye Park, Steven L. Chang, Bradley A. McGregor, Rizwan Haq, Thomas Denize, Sabina Signoretti, Jennifer L. Guerriero, Sébastien Vigneau, Orit Rozenblatt-Rosen, Asaf Rotem, Aviv Regev, Toni K. Choueiri, and Eliezer M. Van Allen

**Figure S1**

**A**



**B**




**Figure S1. Identification of clusters, lineage, and cell subsets. Related to Figure 1.**

(A) UMAP of all malignant and non-malignant cells captured across all lesions, colored by initial Louvain cluster (left), lineage (middle), and final cell type annotation following iterative reprojection and clustering within lineages (right).

(B) Heatmaps of inferred CNV for all cells from two representative samples (P90 and P915). Red indicates amplification, while blue indicates deletion. Malignant clusters were identified through broad copy number alteration profiles, including 3p loss characteristic of ccRCC.

Figure S2

A



B





Figure S2

C





**Figure S2. Metadata and marker expression for all lymphoid cells and CD8<sup>+</sup> T cells. Related to Figure 2.**


(A) Visualization of metadata and associated cell type proportions across lymphoid cells.

(B) Expression heatmaps in UMAP projection space of genes encoding cell type and phenotype markers across lymphoid clusters. MitoHigh cells are omitted.


(C) Expression heatmaps in UMAP projection space of genes encoding co-inhibitory receptors, progenitor and terminal exhaustion markers, effector molecules, and cluster-specific genes across CD8<sup>+</sup> T cell clusters. Bar plots quantify the percentage of cells in each cluster expressing a given gene.

**Figure S3**


**A**




**B**



**C**




**D**



**E**

**GSEA: ICB PR vs ICB SD/PD (Progenitor Exh. Cells only)**



**GSEA: ICB PR vs ICB SD/PD (Progenitor Exh. Cells only)**






Figure S3

F



G



### Figure S3. Transcriptional characteristics of Progenitor and Terminally Exhausted CD8<sup>+</sup> T cells.

#### Related to Figure 2.

(A) Progenitor exhausted signature score versus terminally exhausted signature score for all CD8<sup>+</sup> T cells (n = 7,557), points colored by expression of genes of interest.

(B) Progenitor exhausted signature score versus terminally exhausted signature score for all CD8<sup>+</sup> T cells (n = 7,557), points colored by CD8<sup>+</sup> T cell cluster identity. Progenitor Exhausted and Terminally Exhausted Cells called based on mutually exclusive high/low signature scores. Percentage of total CD8<sup>+</sup> T cell is shown for each quadrant.

(C) Progenitor exhausted signature score versus terminally exhausted signature score for all CD8<sup>+</sup> T cells (n = 7,557), points colored by ICB response group.


(D) Heatmap of scaled, normalized counts averaged within patients for genes differentially expressed between 4-1BB-Lo CD8<sup>+</sup> T cells from ICB PR and ICB SD/PD samples. Effector molecules and co-inhibitory receptors are uniformly upregulated in responding patients, while progenitor exhausted markers, including *TCF7*, are upregulated in non-responding patients.

(E) GSEA of progenitor and terminally exhausted signatures in only Progenitor Exhausted Cells from ICB PR patients compared to ICB SD/PD patients. Key leading edge genes are labeled.

(F) Heatmap of scaled, normalized counts averaged within patients for leading edge genes in GSEA of the terminally exhausted signature in 4-1BB-Lo CD8<sup>+</sup> T cells from ICB PR patients compared to ICB SD/PD patients.

(G) Heatmap of scaled, normalized counts averaged within patients for leading edge genes in GSEA of the progenitor exhausted signature in 4-1BB-Lo CD8<sup>+</sup> T cells from ICB PR patients compared to ICB SD/PD patients.

**Figure S4**



**Figure S4. Metadata for all myeloid cells and differential gene expression programs in tumor associated macrophages. Related to Figure 3.**

(A) Visualization of metadata and associated cell type proportions across myeloid cells.

(B) Heatmap of scaled normalized counts averaged within patients for leading edge genes in GSEA of the M1 Curated signature in GPNMB-Hi TAM from ICB PR patients compared to ICB SD/PD patients.

(C) Heatmap of scaled normalized counts averaged within patients for leading edge genes in GSEA of the GO Antigen Presentation and Processing signature in GPNMB-Hi TAM from ICB PR patients compared to ICB SD/PD patients.

(D) GSEA of M1 Curated, M2 Curated, Hallmark Interferon Gamma Response, and GO Antigen Presentation and Processing via MHC class I signatures in all TAM from ICB PR patients compared to ICB SD/PD patients.

(E) GSEA of M1 Curated, M2 Curated, Hallmark Interferon Gamma Response, and GO Antigen Presentation and Processing via MHC class I signatures in all TAM from ICB SD/PD patients compared to ICB-naive patients.

\*ns: not significant

Figure S5






Figure S5


Advanced ccRCC cases only (n = 6)



CD8<sup>+</sup> T cell Findings



TAM Findings





**Figure S5. Metadata and differential gene expression programs for tumor cells. Analysis showing reproducibility of main findings in CD8<sup>+</sup> T cell, TAM, and tumor compartments when single cell cohort subsetted to include only stage IV lesions of clear cell histology (n = 6). Related to Figure 4.**

(A) Visualization of metadata and associated cell type proportions across tumor cells.

(B) Heatmap of scaled normalized counts averaged within patients for leading edge genes in GSEA of the Hallmark Interferon Gamma Response signature in TP1 cells from ICB PR patients compared to ICB SD/PD patients.

(C) Heatmap of scaled normalized counts averaged within patients for leading edge genes in GSEA of the GO Antigen Presentation and Processing via MHC-I signature in TP1 cells from ICB PR patients compared to ICB SD/PD patients.

(D) Heatmap of scaled normalized counts averaged within patients for leading edge genes in GSEA of the Hallmark Interferon Gamma Response signature in TP2 cells from ICB PR patients compared to ICB SD/PD patients.

(E) Heatmap of scaled normalized counts averaged within patients for leading edge genes in GSEA of the GO Antigen Presentation and Processing via MHC-I signature in TP2 cells from ICB PR patients compared to ICB SD/PD patients. (J) Heatmap of differential gene expression q-values (two-sided Wilcoxon rank-sum test with Bonferroni FDR correction) for comparisons of cells within each CD8<sup>+</sup> T cell cluster from ICB-exposed vs. ICB-naïve patients (advanced ccRCC cases only).

(F) Heatmap of differential gene expression q-values (two-sided Wilcoxon rank-sum test with Bonferroni FDR correction) for comparisons of cells within each CD8<sup>+</sup> T cell cluster from ICB-exposed vs. ICB-naïve patients (advanced ccRCC cases only).

(G) Gene set enrichment analysis (GSEA) of terminally exhausted and progenitor exhausted signatures in 4-1BB-Lo CD8<sup>+</sup> T cells from ICB PR compared to ICB SD patients (advanced ccRCC cases only).

(H) GSEA of M1 Curated, M2 Curated, Hallmark Interferon Gamma Response, and GO Antigen Presentation and Processing via MHC class I signatures in all TAM from ICB PR compared to ICB SD patients (advanced ccRCC cases only).

(I) Violin and box plots comparing expression distributions of immune checkpoint and evasion genes between all TAM from ICB-exposed vs ICB-naïve patients (top) and ICB PR vs ICB SD patients (bottom) (advanced

ccRCC cases only). Significance of differential expression (q-value) was determined by two-sided Wilcoxon rank-sum test with Bonferroni FDR correction. Box plots include center line, median; box limits, upper and lower quartiles; whiskers extend at most 1.5× interquartile range past upper and lower quartiles.

(J) Violin and box plots comparing single cell signature score distributions between the two dominant malignant cell clusters, partitioned by biopsy site (advanced ccRCC cases only). Significance of differential signature enrichment (p-value) was determined by two-sided Wilcoxon rank-sum test. Box plots include center line, median; box limits, upper and lower quartiles; whiskers extend at most 1.5× interquartile range past upper and lower quartiles.


(K) GSEA of Hallmark Interferon Gamma Response and GO Antigen Presentation and Processing via MHC class I signatures in TP1 cells from ICB PR patients compared to ICB SD patients (top) and TP2 cells from ICB PR patients compared to ICB SD patients (bottom) (advanced ccRCC cases only).

(L) Heatmap of differential expression q-values (two-sided Wilcoxon rank-sum test with Bonferroni FDR correction) for immune checkpoint and evasion genes in comparisons of cells within each cluster from ICB-exposed vs ICB-naïve patients (left) and ICB PR vs ICB SD patients (right) (advanced ccRCC cases only).


\*ns: not significant

**Figure S6**


**A**




**B**





**C**



**D**




**Figure S6**




**Figure S6**

**H**



**I**



**Figure S6. Extended clinical and mutational analysis of bulk RNA-Seq samples in the Checkmate 025 RCC cohort. Related to Figure 5.**

(A) On left, violin and box plots showing distributions of TP1 score within CR/PR, SD, and PD response groups in the ICB arm of the Checkmate 025 RCC cohort. Significance of differential signature enrichment (p-value) was determined by two-sided Wilcoxon rank-sum test. On right, Kaplan-Meier analysis of overall survival (OS) in only the SD and PD response groups of Checkmate 025, with patients separated by high and low TP1 score in bulk RNA-seq. Box plots include center line, median; box limits, upper and lower quartiles; whiskers extend at most 1.5× interquartile range past upper and lower quartiles.

(B) On left, violin and box plots showing distributions of Immune Checkpoint/Evasion score within CR/PR, SD, and PD response groups in the ICB arm of the Checkmate 025 RCC cohort. Significance of differential signature enrichment (p-value) was determined by two-sided Wilcoxon rank-sum test. On right, Kaplan-Meier analysis of overall survival (OS) in only the SD and PD response groups of Checkmate 025, with patients separated by high and low Immune Checkpoint/Evasion score in bulk RNA-seq. Box plots include center line, median; box limits, upper and lower quartiles; whiskers extend at most 1.5× interquartile range past upper and lower quartiles.

(C) On left, violin and box plots showing distributions of TP2 score within CR/PR, SD, and PD response groups in the ICB arm of the Checkmate 025 RCC cohort. Significance of differential signature enrichment (p-value) was determined by two-sided Wilcoxon rank-sum test. On right, Kaplan-Meier analysis of overall survival (OS) in only the SD and PD response groups of Checkmate 025, with patients separated by high and low TP2 score in bulk RNA-seq. Box plots include center line, median; box limits, upper and lower quartiles; whiskers extend at most 1.5× interquartile range past upper and lower quartiles.

(D) Kaplan-Meier analysis of overall survival (OS) in the Checkmate 025 RCC cohort, with patients separated by high and low TP2 score in bulk RNA-seq.  $P_{log-rank}$ , log-rank test p-value.  $P_{Cox}$ , p-value determined via a multivariate Cox proportional hazard model using TP2 score dichotomized within treatment arm and incorporating age, sex, MSKCC risk group, prior lines of therapy ( $\leq 1$  or  $\geq 2$ ), and days between biopsy collection and start of trial therapy as covariates.

(E) Bar plots comparing TP1 and TP2 score between mutant and wild-type samples for commonly mutated genes in the TCGA KIRC cohort (Stage III and IV tumors only). Only variants with predicted high impact

Ensembl Sequence Ontology were considered. Significance of differential score enrichment (q-value) determined by two-sided Wilcoxon rank-sum test with Benjamini-Hochberg FDR correction.

(F) Bar plots comparing TP1 and TP2 score between mutant and wild-type samples for common copy number alterations in the TCGA KIRC cohort (Stage III and IV tumors only). Significance of differential score enrichment (q-value) determined by two-sided Wilcoxon rank-sum test with Benjamini-Hochberg FDR correction.

(G) Forest plot showing hazard ratios associated with variables in a multivariate Cox proportional hazard model for OS in the ICB arm of Checkmate 025, incorporating TP1 Score, PBRM1 mutational status, age, sex, MSKCC risk group, prior lines of therapy ( $\leq 1$  or  $\geq 2$ ), and days between biopsy collection and start of trial therapy as covariates.

(H) Bar plots comparing CIBERSORTx-inferred immune population frequencies between Checkmate 025 RCC tumors with high and low TP1 Tumor Program Scores. CIBERSORTx signature matrix was derived from transcriptional profiles of lymphoid and myeloid subsets captured in our cohort. Significance of differential population frequencies (q-value) determined by two-sided Wilcoxon rank-sum test with Benjamini-Hochberg FDR correction. Gray dotted line corresponds to  $q = 0.05$ .

(I) Bar plots comparing CIBERSORTx-inferred immune population frequencies between Checkmate 025 RCC tumors with high and low TP2 Tumor Program Scores. CIBERSORTx signature matrix was derived from transcriptional profiles of lymphoid and myeloid subsets captured in our cohort. Significance of differential population frequencies (q-value) determined by two-sided Wilcoxon rank-sum test with Benjamini-Hochberg FDR correction. Gray dotted line corresponds to  $q = 0.05$ .